Clinical Trial

Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 26, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is an open-label, multicenter Phase II trial, planning to enroll 200 subjects, using BEBT-109 capsules as monotherapy, aimed at evaluating the efficacy and safety of BEBT-109 capsules in subjects with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations in locally advanced or metastatic Non-Small Cell Lung Cancer （NSCLC）.
Trial Details
NCT Number NCT06706713
Lead Sponsor BeBetter Med Inc
Conditions Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
Enrollment 200 participants
Start Date 2022-04-15
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-26